Core Viewpoint - The company has decided not to exercise the right to adjust the conversion price of its convertible bonds, "Xianle Convertible Bonds," despite meeting the conditions for downward adjustment, in order to protect the interests of all investors [10]. Group 1: Convertible Bond Issuance - The company issued 10.2489 million convertible bonds with a total fundraising amount of RMB 1,024.8929 million, netting RMB 1,016.1675 million after expenses [1]. - The bonds were listed on the Shenzhen Stock Exchange on May 14, 2021, under the name "Xianle Convertible Bonds" and code "123113" [2]. - The conversion period for the bonds began on October 25, 2021, following the end of the bond issuance [2]. Group 2: Conversion Price Adjustment - The conversion price was initially set at RMB 85.98 per share and was adjusted to RMB 56.92 per share after a cash dividend and capital increase [2][3]. - Subsequent adjustments to the conversion price occurred on several occasions, with the latest adjustment reducing the price to RMB 31.82 per share effective May 27, 2025 [8]. - The company has the authority to propose a downward adjustment of the conversion price if the stock price falls below 85% of the conversion price for at least 15 trading days within a 30-day period [9]. Group 3: Board Decisions - The company's board of directors convened on July 30, 2025, and decided not to propose a downward adjustment of the conversion price for the next six months, even if the conditions for adjustment are met again [10]. - This decision was made to maintain investor confidence and protect the interests of all stakeholders [10].
仙乐健康: 关于不向下修正仙乐转债转股价格的公告